ArticleAnalytical and bioanalytical chemistry2026
Polyaniline-gold nanoparticle-based biosensor targeting miR-21-5p for early diagnosis of leptospirosis.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Blood-based disease diagnosis facilitates the early-stage detection of leptospirosis because leptospires were present in the blood in the first 5 to 10 days after exposure. We present a sensor employing polyaniline (PANI) and gold nanoparticles (AuNPs) for the specific detection of miR-21-5p in individuals with leptospirosis. The electropolymerization of PANI on glassy carbon electrodes (GCEs) creates a porous and durable coating that remains stable over extended periods without mechanical damage. To enhance the biosensor's performance, we functionalized the sensor surface with gold nanoparticles through electrodeposition, which facilitated an electroactive surface and selective binding of the thiolated probe. Our data confirmed that the thiolated DNA probe (anti-miRNA-21) exhibits a higher affinity for the target miRNA-21 and serum samples from individuals with leptospirosis compared to non-complementary sequences and healthy serum samples. The biosensor demonstrated remarkable sensitivity with a detection range spanning from 1 aM to 50 nM, boasting a limit of detection (LOD) of 1 aM and a limit of quantification (LOQ) of 4.59 aM. This represents an unprecedented achievement in ultra-low-level miRNA-based biosensors for diagnosing leptospirosis. Early-stage disease detection is crucial for effective disease management and timely treatment. Such an approach holds promise for point-of-care testing in remote settings to facilitate the early diagnosis of leptospirosis.
Indexed as
Identifiers
42642667What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.